CAJ | 학술논문

异基因干细胞移植是惟一可能治愈多发性骨髓瘤(MM)的临床方法.较高的移植相关死亡率(TRM)限制了清髓性异基因干细胞移植在临床的广泛应用；非清髓性异基因干细胞移植降低了TRM,但疾病复发和进展的风险却增加；自体-非清髓性异基因干细胞串联移植,在降低TRM的同时,可有效减少疾病的复发和进展.目前临床上亦存在很多可能提高MM移植疗效的新方法.
이기인간세포이식시유일가능치유다발성골수류(MM)적림상방법.교고적이식상관사망솔(TRM)한제료청수성이기인간세포이식재림상적엄범응용；비청수성이기인간세포이식강저료TRM,단질병복발화진전적풍험각증가；자체-비청수성이기인간세포천련이식,재강저TRM적동시,가유효감소질병적복발화진전.목전림상상역존재흔다가능제고MM이식료효적신방법.
Allogeneic stem cell transplantation is the only treatment which may cure multiple myeloma (MM).The high transplantation related mortality (TRM) limits the wide clinical application of myeloablative allogeneic stem cell transplantation.Non-myeloablative allogeneic stem cell transplantation can reduce the TRM,but the risk of relapse and progress of the disease may get increased. Autononmyeloablative allogeneic stem cell tandem transplantation can reduce both the TRM and the relapse and progress of the disease. At present,there exist many new methods which may improve the effect of allogeneic stem cell transplantation for MM in clinical.